mycobacterium tuberculosis
در نشریات گروه پزشکی-
زمینه
از اهداف سازمان بهداشت جهانی، کاهش شیوع بیماری سل به کمتر از یک مورد در هر یک میلیون نفر تا سال 2050 می باشد. برای رسیدن به این هدف تشخیص سریع بیماری، ارائه درمان موثر و شناسایی سویه های مقاوم به دارو اهمیت بسیاری دارد. بر این اساس این مطالعه با هدف شناسایی مقاومت نسبت به اتامبوتول در بیماران مسلول مراجعه کننده به مرکز بهداشت اردبیل طراحی گردید.
روش کاردر این مطالعه مقطعی -توصیفی، بین سال های 96-99، 71 نمونه بالینی از بیماران مراجعه کننده به مرکز بهداشت اردبیل جمع آوری شد. نمونه ها ابتدا با روش میکروسکوپیک بررسی شده سپس با روش جوشاندن، DNA استخراج شد. به کمک پرایمرهای اختصاصی و تکنیک PCR حضور سویه های کمپلکس سلی و به دنبال آن مقاومت نسبت به اتامبوتول بررسی گردید.
یافته هااز 71 نمونه بالینی مورد بررسی 6 نمونه (8/45%) NTM بودند. از کل نمونه های مورد بررسی، 36 نمونه (50/7%) دارای موتاسیون ژن embB 306 بودند که از این تعداد 3 نمونه NTM بودند، کل مقاوم های NTM 50٪ بود). در بین ایزوله های مقاوم به اتامبوتول، در 6 نمونه، لود باکتری 1 مثبت بود (16/67%)، در 8 نمونه لود باکتری 2 مثبت بود (22/22%) و در بقیه همگی 3 مثبت یا بالاتر بودند (61/11%).
نتیجه گیریدر این مطالعه میزان فراوانی مقاومت نسبت به اتامبول 50/7% بود که درصد بالایی را نشان می دهد. همچنین این مطالعه نشان داد که روش MAS-PCR روشی سریع، ارزان و موثر برای شناسایی مقاومت نسبت به داروهای خط اول سل مانند اتامبوتول می باشد. به کمک این روش می توان همزمان مقاومت نسبت به بقیه داروهای خط اول را نیز بررسی کرد و با تشخیص سریع مقاومت های آنتی بیوتیکی و درمان موثرتر سویه های مقاوم از گسترش سویه های مقاوم در جامعه پیشگیری کرد.
کلید واژگان: مایکوباکتریوم توبرکلوزیس، DNA، اتامبوتول، MAS-PCRBackgroundGlobal stop TB is a critical strategy which aims at reducing the incidence of tuberculosis to less than one case per one million people by 2050. To achieve this goal, it is necessary to establish a timely diagnosis of the disease, provide an effective treatment, and identify the drug-resistant strains. Therefore, this study aimed to identify the resistance to ethambutol in patients referred to Ardabil Health Center.
MethodsIn this descriptive cross-sectional study, 71 clinical samples were collected from the patients referred to Ardabil Health Center between 2017-2020. The samples were first examined adopting microscopic method, and then DNA was extracted using the boiling method. Specific primers and MAS-PCR technique were employed for identification of ethambutol resistance strains.
ResultsOut of 71 collected specimens, six samples were NTM (8.45%). Out of all the examined samples, 36 samples (50.7%) had embB306 gene mutation, of which three samples were NTM (total NTM resistance was 50%). Out of the samples identified as resistant to ethambutol, six samples had a low bacterial load as +1 (16.67%), eight samples had a moderate bacterial load as +2 (22.22%), and the rest had a high bacterial load as +3 (61.11%).
ConclusionIn sum, the frequency of resistance to ethambutol was 50.7%, which was higher than that reported by previous similar studies. Furthermore, it was determined that the MAS-PCR method was a fast, cheap, and reliable method for identifying resistance to the first-line tuberculosis drugs such as ethambutol. Therefore, this method may have facilitated evaluating the resistance to other first-line drugs at the same time and preventing the spread of resistant strains in the community through early detection of the antibiotic resistance.
Keywords: Mycobacterium Tuberculosis, DNA, Ethambutol, MAS-PCR -
Background
Tuberculosis (TB) remains a global health challenge, particularly due to drug resistance and limitations in rapid diagnosis. Next-generation sequencing (NGS), especially long-read whole genome sequencing (WGS), shows promise for rapidly detecting TB and drug resistance, but it requires high-quality DNA, which is difficult to extract from Mycobacterium tuberculosis due to its complex cell wall.
ObjectivesThis study evaluated four DNA isolation methods for extracting pure DNA from M. tuberculosis , aiming to standardize protocols for long-read WGS.
MethodsMycobacterium tuberculosis H37RV colonies were grown in BACTEC MGIT liquid medium. Two pellets were prepared as the initial material for the DNA extraction protocol: Pellets from 1 mL McFarland 2 suspensions and all growing colonies from two MGIT liquid cultures. Four DNA extraction methods were used: The cetyltrimethylammonium bromide (CTAB) method, GeneJET Genomic DNA Purification Kit, Quick-DNA Fecal/Soil Microbe Kit, and Genematrix Tissue/Bacterial DNA Purification Kit, with some modifications. DNA quality was assessed based on concentration, purity, and integrity.
ResultsAmong the tested methods, the Quick-DNA Fecal/Soil Kit yielded approximately 85 ng/mL of DNA and a purity of 1.9 at 260/280 nm from the colonial pellet of two MGIT tubes. However, lower intact DNA [DNA integrity number (DIN) ~ 6.8] was obtained with this kit. The CTAB method provided the highest intact DNA (DIN ~ 9.5), although the purity of the DNA was not sufficient.
ConclusionsBased on three repetitions of McF-2 and colonial pellet extractions, the Quick-DNA Fecal/Soil Kit yielded the highest DNA quantity and purity but showed lower integrity compared to other methods, indicating the need for adjustments. A pellet from two MGIT cultures (~ 100 µL) is suitable for long-read WGS with this kit. However, a larger sample size is required to generalize these findings. For effective long-read sequencing of M. tuberculosis , DNA extraction protocols must be optimized to balance yield, fragment size, and purity for accurate sequencing and drug resistance analysis.
Keywords: Mycobacterium Tuberculosis, Whole Genome Sequencing, Next Generation Sequencing, Nanopore Sequencing, DNA, Isolation, Purification -
باوجود کاهش میزان سل در سراسر جهان، موارد جدیدی از این بیماری همچنان در ایران گزارش می شود، اما سل پوستی غیر شایع و بخش کوچکی از موارد جدید را به خود اختصاص می دهد. مشابهت ظاهری زخم پوستی ایجادشده به دلیل سل پوستی با سایر بیماری های سیستمیک ازنظر بالینی چااش برانگیز است. سل جلدی به دو نوع تقسیم می شود: نوع واقعی که با تشخیص باسیل از پوست درگیر مشخص می شود و نوع توبرکلوئید که ناشی از واکنش حساسیت مفرط استمقاله حاضر موردی را بررسی می کند که در آن پس از نمونه برداری سوزنی تحت هدایت سی تی اسکن از ریه، سل پوستی در محل سوزن بیوپسی به شکل ندول زخمی پوست ظاهر شده است. این گزارش موردی بر اهمیت شرح حال و معاینه فیزیکی تاکید دارد و توجه پزشکان را به احتمال انتشار بیماری از طریق روش نمونه گیری سوزنی با هدایت سی تی اسکن جلب می کند.
کلید واژگان: سل جلدی، مایکوباکتریوم توبرکلوزیس، زخم نکروزان، درد پلورتیکDespite the reduction of tuberculosis globally, new cases of this disease continue to be reported in Iran, although skin tuberculosis is uncommon and constitutes a small portion of new cases. The presentation of skin ulcers caused by cutaneous tuberculosis can mimic other systemic diseases, leading to clinical uncertainty. Cutaneous tuberculosis is classified into two types: the true type, characterized by the presence of bacilli in the affected skin, and the tuberculoid type, resulting from an allergic reaction.This case report highlights a situation where a skin nodule, initially identified as cutaneous tuberculosis, was later confirmed through a lung biopsy guided by CT scan. It emphasizes the significance of medical history, physical examination, and considering the potential risk of disease spread during needle sampling procedures guided by CT scans.
Keywords: Cutaneous Tuberculosis, Mycobacterium Tuberculosis, Necrotizing Wound, Skin Ulcer, Pleuritic Pain -
Background and Objectives
TB infection is one of the most challengeable epidemiological issues. Complex interactions between microbiota and TB infection have been demonstrated. Alteration in microbial population during TB infection may act as a useful biomarker. The present study examined the microbiota patterns of blood and sputum samples collected from Afghan immigrants and Iranian patients with active TB.
Materials and MethodsSixty active pulmonary TB patients were enrolled in the study. Blood and sputum samples were collected. To detect phylum bacterial composition in the blood and sputum samples, bacterial 16S rRNA quantification by Real-Time qPCR was performed.
ResultsA significant decrease in Bacteroidetes in Iranian sputum and blood samples of Afghan immigrants and Iranian TB active subjects were seen. While, sputum samples of Afghan immigrants showed no significant differences in Bacteroidetes abundance among TB active and control. Firmicutes were also presented no significant difference between sputum samples of the two races. Actinobacteria showed a significant increase in Iranian and Afghan sputum samples while this phylum showed no significant abundance in Iranian and Afghan TB positive blood samples. Proteobacteria also showed an increase in sputum and blood samples of the two races.
ConclusionAn imbalance in Bacteroidetes and Firmicutes abundance may cause an alteration in the microbiota compo- sition, resulting in dysregulated immune responses and resulting in the augmentation of opportunistic pathogens during TB infection, notably Proteobacteria and Actinobacteria. Evaluation of human microbiota under different conditions of TB infection can be critical to a deeper understanding of the disease control.
Keywords: Mycobacterium Tuberculosis, Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria -
مجله دانشکده پزشکی دانشگاه علوم پزشکی مشهد، سال شصت و هفتم شماره 2 (پیاپی 194، خرداد و تیر 1403)، صص 332 -340سابقه و هدف
سل معضلی قدیمی است که هم اکنون به عنوان چالشی جدید مطرح است. مطالعه حاضر با هدف بررسی تنوع ژنتیکی سویه های مایکوباکتریوم توبرکلوزیس جدا شده از بیماران مبتلا به سل در کرج، ایران انجام شد.
مواد و روش هاهفده جدایه مایکوباکتریوم توبرکلوزیس از سال 2012 تا 2013 جمع آوری شد و تحت آنالیز پلی مورفیسم طول قطعه محدود IS6110 (IS6110-RFLP) قرار گرفتند. از نظر جمعیت شناختی، 6 زن و 14 مرد دارای تابعیت ایرانی در این مطالعه وارد شدند.
نتایج16 نوع ژنتیکی مختلف پس از هضم آنزیمی و تجزیه و تحلیل RFLP به دست آمد. تعداد کپی IS6110 در هر ایزوله از 0 تا 12 متغیر بود. اکثر ایزوله ها (66%) دارای اعداد کپی بین 6 تا 12 بودند. هر ایزوله دارای 6.9 کپی از نشانگر IS6110 بود. 9 جدایه دارای 10 تا 12 نسخه از نشانگر IS6110، 5 ایزوله دارای 6 تا 10 نسخه، و 2 ایزوله دیگر دارای نسخه های کمتر از 6 بودند. هیچ نسخه ای از IS6110 در بین 4 ایزوله یافت نشد. هیچ رابطه ای بین جنسیت و تعداد کپی یافت نشد.
نتیجه گیریتنوع ژنتیکی بالای موجود در جدایه های مایکوباکتریوم توبرکلوزیس ممکن است منابع مختلف عفونت و اهمیت ظهور مجدد سل را نشان دهد.با این حال، بررسی های بیشتر باید برای ارزیابی سایر جنبه های اپیدمیولوژیک مولکولی مایکوباکتریوم توبرکلوزیس در ایران انجام شود.
کلید واژگان: مایکوباکتریوم توبرکلوزیس، تنوع ژنتیکی، IS6110-RFLP، ایرانBackground and aimTuberculosis (TB) is an old issue that is presently measured as a significant challenge. The present survey was aimed to assess the genetic diversity of M. tuberculosis strains isolated from patients with TB in Karaj, Iran.
MethodsSeventeen M. tuberculosis isolates from 2012 to 2013 were collected and subjected to an IS6110 restriction fragment length polymorphism (IS6110-RFLP) analysis. Demographically, 6 females and 14 males who had Iranian citizenship were included in this study.
ResultsSixteen different genetic types were obtained after enzymatic digestion and RFL analysis. Copy numbers of IS6110 in each isolate ranged from 0 to 12. The majority of isolates (66%) harbored copy numbers between 6 and 12. Each isolates harbored 6.9 copies of the IS6110 marker. Nine isolates harbored 10 to 12 copies of the IS6110 marker, 5 isolates harbored 6 to 10 copies, and 2 others harbored copies less than 6. No copy of IS6110 was found among the 4 isolates. No relationship was found between gender and copy numbers.
ConclusionThe high genetic diversity found amongst the M. tuberculosis isolates maybe show different sources of infection and the importance of reemerging of the TB. However, further surveys should perform to assess other molecular epidemiologic aspects of M. tuberculosis in Iran.
Keywords: Mycobacterium Tuberculosis, Genetic Diversity, IS6110-RFLP, Iran -
Objective (s)
Tuberculosis (TB) has been a major health issue throughout history. As part of TB infection, host-Mycobacterium tuberculosis (Mtb) interactions are important. Through immune pathology and cell death control processes, Mtb infection facilitates intracellular growth. The relationship between apoptosis and inflammation in Mtb infection remains unclear. In this study, the levels of related apoptosis and inflammatory genes were assessed in A549 cells infected with a variety of Mtb strains.
Materials and MethodsMtb isolates with different phenotypes (sensitive, INHR, RifR, MDR, and XDR) were collected from the Pasteur Institute of Iran, during this study. Whole genome sequencing was previously performed on all strains, and the Beijing genotype was selected as sensitive. Also, for other resistant strains, the New-1 genotype was available and isolated for genotype comparison. A549 lung carcinoma cells were also grown and infected with selected Mtb strains. Genes involved in inflammation and apoptosis were detected using reverse transcription-PCR (RT-PCR).
ResultsAll sensitive strains and resistant strains were found to significantly up-regulate anti-apoptotic (bcl2 and rb1), chemokine (IL-8 and MCP-1), and pro-inflammatory cytokine (TNF-α and IFN-γ) expression, while significant down-regulation was observed after 24 and 48 hr of infection in anti-inflammatory genes (IL-10) and pro-apoptotic genes (bad and bax). Besides resistance strains, Mtb genotypes also affected gene expression. The Beijing genotype (sensitive isolate) influences inflammatory and apoptotic genes more sharply than the New-1 genotype (INHR, RifR, MDR, and XDR).
ConclusionGene expression differences related to apoptosis and inflammation examined in the current study may be attributed to genotypes rather than resistance status since the expression of most genes has been observed to be lower in resistant strains (INHR, RifR, MDR, and XDR belonging to the New-1 genotype) compared to sensitive strains (Beijing genotype).
Keywords: Alveolar epithelial cell, Drug resistance, Immune system, Mycobacterium tuberculosis, Programmed cell death -
Objective (s)
Tuberculosis (TB) is one of the most common infectious diseases in the world and requires novel medications or existing ones should be improved. Nanotechnology is a modern science that helps to avoid adverse reactions and resistance to drugs. The current regimen for standard therapy calls for routine administration of medications over six months. Since the noncompliance of patients and the emergence of drug-resistant strains, therapies become more challenging. The objective of the current study was to develop Isoniazid-Rifampicin-loaded (INH-RIF-NPs) nanoparticles to improve release properties and drug encapsulation efficiency.
Materials and MethodsBox-Behnken Design (BBD) was used for optimizing the nanoparticles. Eudragit was used in the preparations in varying concentrations (1-2% w/v). The compatibility of the drug and excipients was shown. The existence of the nanoparticles was confirmed by the analytical results of the transmission electron microscopy (TEM) and Fourier transform infrared spectroscopy (FTIR).
ResultsThe optimized nanoparticles showed no drug-polymer interaction. The mean size of the INH-RIF-NPs was around 112±8.73 nm, and they were sphere-like, smooth, fairly uniform in size, and well-dispersed, and entrapment efficiencies were high at 98.7±0.68%. Drug release was slow and sustained with 66.91% INH cumulative release and 80.06 of RFP after 24 hr.
ConclusionSignificant drug uptake with higher encapsulation efficiency, uniform size, good dispersion, and prolonged release characteristics are all present in INH-RIF-NPs. This suggests the existence of a delivery system capable of effectively encapsulating and delivery of combined drug formulation in polymeric nanoparticles.
Keywords: Drug Delivery System, Isoniazid, Mycobacterium Tuberculosis, Nanoparticles, Rifampicin -
سابقه و هدف
در دسامبر 2019 مجموعه ای از موارد پنومونی با منشا ناشناخته در ووهان چین گزارش شد که توسط سازمان بهداشت جهانی به عنوان COVID-19 نامگذاری شد. عوامل خطر ایجاد بیماری کووید-19 هنوز به خوبی شناخته شده نیست، اما شواهد نشان می دهد برخی عوامل از جمله بیماری های تنفسی مانند بیماری سل، از فاکتورهای خطر مهم در بیماری کووید-19 هستند. لازم به ذکر است، بیماری سل مانند SARS-COV-2، عمدتا از طریق تنفسی منتقل می شود و ریه ها را تحت تاثیر قرار می دهد. هم چنین برخی مطالعات نشان می دهد که عفونت همراه با مایکوباکتریوم توبرکولوزیس سبب ایجاد علایم پنومونی با سرعت بیش تر و شدیدتر در کووید-19 و عامل عمده مرگ به علت بیماری شدید ایجاد شده می باشد. با توجه به این که، بیماری کووید-19 یک پاندمی نوپدید بوده و عوامل خطر مرتبط با بروز و شدت آن هم چنان در حال بررسی است و با توجه به این که بیماری سل از بیماری های عفونی قابل درمان است که می تواند بر سایر بیماری های تنفسی اثر گذار باشد، این مطالعه با هدف بررسی فراوانی کووید-19 محتمل و قطعی در دو پیک اول و دوم پاندمی کرونا در بین مبتلایان با سابقه ابتلا به سل، انجام پذیرفت.
مواد و روش هااین مطالعه به صورت توصیفی- مقطعی، بوده است و جمعیت مورد مطالعه شامل بیماران با سابقه ابتلا به سل که تاریخ تشخیص آن ها در بازه زمانی 1394 الی 1399 بوده است. تعداد این نمونه ها برابر 1532 بوده است. روش نمونه گیری، سرشماری بوده است. زمان بررسی از نظر ابتلا به کووید-19 بعد از پیک اول و در طول و بعد از پیک دوم کرونا (از نیمه دوم اردیبهشت 1399 الی آبان 1399) بوده است. ابزار گردآوری اطلاعات شامل چک لیست حاوی متغیرهای دموگرافیک و علایم کلینیکی مرتبط با کووید-19 بوده است. روش گردآوری اطلاعات به صورت مصاحبه تلفنی و بررسی مستندات بود. جمع آوری اطلاعات توسط پرسشگران آموزش دیده انجام گرفت. بدین منظور، ابتدا به پرسشگران آموزش لازم خصوص نحوه تکمیل چک لیست ارائه شد. ورود داده در نرم افزار اکسل انجام و جهت آنالیز به نرم افزار SPSS ver.16 انتقال داده شد. توصیف متغیرها بر حسب تعداد، درصد، میانگین، انحراف معیار و میانه ارائه شده است. مقایسه بین متغیرهای گروه بندی شده با ازمون کای اسکوئر انجام گرفت.
یافته هادر این مطالعه، شیوع موارد کووید-19 محتمل و قطعی در بین بیماران با سابقه ابتلا به سل مورد بررسی، 5/5 درصد (85 نفر) و مورد مشکوک، محتمل و قطعی 6/15 درصد (239 نفر) گزارش شد. هم چنین ارتباطی بین گروه های سنی، جنسیت، محل سکونت، نوع بیماری سل، تاهل، دیابت، بیماری کلیوی و دیالیز، نقص ایمنی و بیماری کبدی با شیوع کووید-19 در بین بیماران با سابقه ابتلا به سل مورد بررسی مشاهده نشد. لازم به ذکر است، در این گروه از مبتلایان، بیماری قلبی، ریوی، سرطان و شیمی درمانی، فشارخون بالا و بیماری های مغز و اعصاب با شیوع کووید-19 مرتبط بود. هم چنین بیش ترین میزان فراوانی کووید-19 مشکوک، محتمل و قطعی در بین بیماران با سابقه سل تشخیص داده شده به ترتیب در سال 1399 با 5/38 درصد (25 از 65 مورد با سابقه بیماری سل)، سال 139 با 7/26 درصد (63 از 236 مورد با سابقه بیماری سل) و سال 1398 با 8/20 درصد (58 نفر از 279 مورد با سابقه سل) بوده است.
استنتاجبه نظر می رسد علی رغم محدودیت قرنطینه ای شدید در ابتدای پاندمی کووید-19 و احتمالا خود قرنطینه ای بالا در مبتلایان به سل به دلیل در معرض خطر بودن ازنظر سن بالا، ابتلا به بیماری های زمینه ای ابتلا مبتلایان به سل به کووید-19 نسبتا قابل ملاحظه بوده است.
کلید واژگان: کووید-19، بیماری سل، مایکوباکتریوم توبرکلوزیس، پاندمی، بیماری های تنفسیBackground and purposeIn December 2019, a series of pneumonia cases of unknown origin were reported in Wuhan, China, named by the World Health Organization as COVID-19. The risk factors for developing the disease of COVID-19 are still not well known, but evidence shows that some factors, including respiratory diseases such as tuberculosis, are important risk factors in the disease of COVID-19. It should be noted that tuberculosis, like SARS-COV-2, is mainly transmitted through breathing and affects the lungs. Also, some studies show that infection with Mycobacterium tuberculosis causes more rapid and severe pneumonia symptoms in COVID-19 and is the main cause of death due to severe disease. Considering that the disease of COVID-19 is a newly emerging pandemic and the risk factors related to its incidence and severity are still being investigated and considering that tuberculosis is a curable infectious disease that can affect other respiratory diseases. This study was conducted to investigate the probable and definite frequency of COVID-19 (COVID-19) in the first and second peaks of the coronavirus pandemic among patients with a history of tuberculosis.
Materials and methodsThis study was descriptive-cross-sectional and the study population included patients with a history of tuberculosis whose diagnosis date was between 2015 and 2020. The number of these samples was equal to 1532. The sampling method was census. The time of investigation in terms of contracting COVID-19 was after the first peak and during and after the second peak of Corona (from the second half of May 2019 to November 2019). The data collection tool included a checklist containing demographic variables and clinical symptoms related to COVID-19. The method of collecting information was in the form of telephone interviews and document review. Data collection was done by trained interviewers. For this purpose, the questioners were first given the necessary training on how to complete the checklist. Data entry was done in Excel software and transferred to SPSS V.16 software for analysis. The description of the variables is presented in terms of number, percentage, mean, standard deviation, and median. A chi-square test was conducted to compare the grouped variables.
ResultsIn this study, the prevalence of probable and definite cases of COVID-19 among patients with a history of tuberculosis was reported as 5.5% (85 people), and suspected, probable and definite cases were reported as 15.6% (239 people). Also, there was no correlation between age groups, gender, place of residence, type of tuberculosis, marriage, diabetes, kidney disease dialysis, immunodeficiency,, and liver disease with the prevalence of COVID-19 among patients with a history of tuberculosis. It should be noted that in this group of patients, heart disease, lung disease, cancer, chemotherapy, high blood pressure, and brain and nerve diseases were related to the spread of COVID-19. Also, the highest frequency of suspected, probable, and definite COVID among patients with a history of tuberculosis was diagnosed respectively in 2019 with 38.5% (25 out of 65 cases with a history of tuberculosis), in 2014 with 26.7% (63 out of 236 cases with a history of tuberculosis) and 20.8% (58 people out of 279 cases with a history of tuberculosis) in 2018.
ConclusionDue to the significant difference in the prevalence of Covid 19 in patients who have not received the flu vaccine, it is necessary to inject the flu vaccine in these patients. Advice to quit smoking in these patients should be a priority. Because no independent study on Covid disease was observed in patients with tuberculosis, further studies in this field are necessary.
Keywords: Covid-19, Tuberculosis, Mycobacterium Tuberculosis, Pandemic, Respiratory Diseases -
BACKGROUND
Isoniazid (INH) is one of the first-line drugs used for the treatment of Mycobacterium tuberculosis (Mtb). This study aimed to determine the mutations in katG and inhA promoter regions associated with INH resistance in clinical isolates of Mtb from Tehran, Iran.
METHODSThis descriptive cross-sectional study was conducted in the tuberculosis (TB) center of Tehran in 2020. 50 samples obtained from these patients were cultured on Löwenstein-Jensen medium (LJ), then, INH-resistant strains and their minimum inhibitory concentration (MIC) were determined using the proportional method. To determine the INH-resistance mutations, sequencing was performed following the amplification of both katG and inhA genes using real-time polymerase chain reaction (PCR). The genetic relationships were determined based on each strain's genetic pattern using the primers related to enterobacterial repetitive intergenic consensus PCR (ERIC-PCR), which is a proper tool used for typing Mtb strains. In this study, the phylogenetic tree was plotted using NTSYS software.
RESULTSFive INH-resistant Mtb strains were isolated from 50 patients with TB in Tehran. All the studied resistant strains (100%) showed a mutation in codon 315 of the katG gene; none of them exhibited any mutation in the promoter. I335T mutation was observed in one INH-resistant strain (20%). The phylogenetic tree of the strains indicated seven clusters as well as 31 patterns in the strains. The strain with two mutations in 335 and 315 had MIC > 8.
CONCLUSIONKatG mutation could result in a high level of INH resistance. Therefore, routine identification of this mutation can help in determining the INH resistance, thereby preventing further propagation of these strains.
Keywords: Mycobacterium Tuberculosis, Resistance, Isoniazid, Mutation, Katg, Inha -
زمینه و هدف
پیرازینامید یکی از داروهای موثر بر درمان بیماری سل است. استفاده این دارو در رژیم درمانی باعث کوتاه شدن مدت زماندرمان سل میشود. وجود جهش در ژن pncA موجب از بین رفتن فعالیت پیرازینامیداز میشود که مهمترین مکانیسم مقاومت در ایزوله هایمایکوباکتریوم توبرکلوزیس است. بنابراین هدف از انجام این مطالعه بررسی مقاومت فنوتیپی و ژنوتیپی به آنتیبیوتیک پیرازینامید درایزوله های مایکوباکتریوم توبرکلوزیس مقاوم به چند دارو) MDR (در استان خوزستان در بازه زمانی 1401 - 1395 میباشد.
روش بررسیاین مطالعه بر روی 40 ایزوله های مایکوباکتریوم توبرکلوزیس در آزمایشگاه منطقهای سل اهواز انجام شد. تعیین حساسیتدارویی ایزوله ها به روش نسبی در آنتی بیوتیک پیرازینامید در ایزوله ها انجام گرفت. سپس تعیین فراوانی موتاسیونهای ژن pncA مرتبط بامقاومت پیرازینامید در ایزوله های MDR با استفاده از تعیین توالی انجام گرفت.
یافته هادر نتایج تست حساسیت دارویی نسبت به آنتیبیوتیک های ریفامپین و ایزونیازید تعداد 25 ایزوله که 16 سویه آن مقاوم به دو دارویایزونیازید وریفامپین (MDR-TB) و 9 ایزوله مقاوم تک دارویی) 8 ایزوله مقاوم به ریفامپین و 1 ایزوله مقاوم به ایزونیازید(به دست آمد. از 17نمونه ای که دارای ژن pncA و مقاوم به پیرازینامید بودند 13 ایزوله دارای موتاسیون در ژن pncA و 4 ایزوله فاقد هر گونه موتاسیون بودند.شایعترین موتاسیون، جهشهای غیر متشابه ، Non synonymous بود که در آن اسید آمینهی Val به Phe تبدیل شده است
نتیجه گیرینتایج این مطالعه نشان داد با توجه به فراوانی مقاومت به پیرازینامید در سویه های MDR ، تک مقاومتی و همچنین درصد بالایجهش در ژن pncA و شیوع کمتر جهش در ژنهای panD و rpsA ،که اطلاعات سریع و دقیقی در مورد حساسیت به پیراینامید برای ایزوله هایMDR-TB و تک مقاومتی فراهم میکند، بهترین روش تشخیص مقاومت به پیرازینامید توالی یابی و سکانس DNA کل pncA برای تایید مقاومتبه پیرازینامید به جای روش های معمول با پوشش نقاط داغ) hotspots (جهش یافته موثرتر است .
کلید واژگان: مایکوباکتریوم توبرکلوزیس، بیماری سل، پیرازینامید، مقاومت آنتی بیوتیکی، سل مقاوم به چند داروBackground and ObjectivesPyrazinamide is one of the effective drugs for treating tuberculosis. Inclusion of this drug in the treatment regimen shortens the duration of tuberculosis treatment. The mutation in pncA gene causes loss of pyrazinamidase activity, the most important resistance mechanism in Mycobacterium tuberculosis isolates. Therefore, the purpose of this study is to investigate the phenotypic and genotypic resistance to pyrazinamide antibiotic in multidrug-resistant (MDR) Mycobacterium tuberculosis isolates in Khuzestan province between 2017 and 2022.
Subjects and MethodsThis study was conducted on 40 isolates of Mycobacterium tuberculosis in Ahvaz TB Regional Laboratory. Drug sensitivity of the isolates was determined by the relative method in the antibiotic pyrazinamide in the isolates. Then, the frequency of pncA gene mutations related to pyrazinamide resistance in MDR isolates was determined using sequencing.
ResultsAccording to the results of the drug sensitivity to rifampin and isoniazid antibiotics, there were 25 isolates, of which 16 strains were resistant to two drugs, namely isoniazid and rifampin (MDR-TB), and 9 were single-drug resistant isolates (8 isolates resistant to rifampin and 1 isolate resistant to Isoniazid). Of the 17 samples that had the pncA gene and were resistant to pyrazinamide, 13 had mutations in the pncA gene while 4 did not have any mutations. The most common mutation was a non-synonymous mutation in which the amino acid Val had changed to Phe.
ConclusionAccording to the results of this study, there is a high frequency of resistance to pyrazinamide in MDR strains. Also, there is a high percentage of single-resistance mutations in the pncA gene, while there is lower prevalence of mutations in the panD and rpsA genes, which provide quick and accurate information about the sensitivity to pyrazinamide for MDR-TB and mono-resistant isolates. Therefore, the best method for detecting resistance to pyrazinamide is sequencing and whole pncA DNA sequence to confirm pyrazinamide resistance instead of the usual methods covering mutated hotspots.
Keywords: Mycobacterium Tuberculosis, Tuberculosis Disease, Pyrazinamide, Antibiotic Resistance, Multi-Drug Resistant Tuberculosis -
Background
Indonesia has the second highest tuberculosis (TB) cases globally. This study aimed to determine the sociodemographic factors associated with TB and rifampicin-resistant tuberculosis (RR-TB) cases among presumptive pulmonary TB patients in Aceh Referral Hospital.
Study Design:
A retrospective cross-sectional study.
MethodsA retrospective cross-sectional review of presumptive pulmonary TB patients having a sputum test at the clinical microbiology laboratory was conducted from January 2015 to December 2021. Patient characteristics and drug susceptibility data were abstracted from the hospital information system of TB (SITB) and analyzed by univariate and bivariate analysis.
ResultsThe Mycobacterium tuberculosis (MTB) was detected in 32.8% sample (1,521/4,637). Of the TB-confirmed cases, 14.1% (215/1,521) were resistant to rifampicin (RR-TB). Most of them were male patients (71.63%), were in the age range of 35–54 years (48.7%), lived in rural areas of the country (56.3%), and were previously TB-treated cases (65.5%). Overall, 35–44-year-old patients (adjusted odds ratio [AOR]=2.11, 95% CI=1.25, 3.5, P<0.05) were more likely to have RR-TB compared to>65-year-old patients. Gender and residence were not associated with RR-TB (P>0.05). Case detection decreased in pandemic conditions (19.5% in 2019 to 13.9% and 7.91% in 2020 and 2021, respectively).
ConclusionThe findings revealed the dynamic cases and sociodemographic factors of TB and RR-TB in a province referral hospital in Indonesia for 7 years. The cases of TB and RR-TB among presumptive TB patients were 32.8% and 14.1%, respectively. The cases were found to be more noticeable in males, adults (45–54 years old), and patients residing in rural areas.
Keywords: Mycobacterium tuberculosis, Indonesia, Sociodemographic factors -
Background
Mycobacterium tuberculosis is still one of the most dangerous human pathogens. Identification of the relationships between different clinical strains has remained a high priority for epidemiology research.
MethodsIn this study, we used MLSA (Multilocus sequence analysis) to generate a highly robust phylogeny of M. tuberculosis. MLSA, based on single nucleotide polymorphism (SNP) was performed on five genes fragments from the Rpsl (302 bp), MprA (559 bp), LipR (322 bp), KatG (488 bp) and Fgd1 (266 bp), in order to identify polymorphic nucleotide sites, and the discriminatory power of each locus for all genes was measured with Hunter‐Gaston Index (HGI).
ResultsIn this study, a sequence type (ST) number was assigned to each unique allelic profile, and 9 sequence types were identified from 20 strains, these imply that there is a high diversity of strains in this area.
ConclusionOur results showed that the presence of high genetic diversity among clinical isolates of M. tuberculosis in Northeast of Iran. There is no evidence for recent transmission. Keywords: Mycobacterium tuberculosis, Multi-locus sequence analysis; Molecular epidemiology; Tuberculosis; KatG; Rpsl1. IntroductionMycobacterium tuberculosis (M. tuberculosis), the causative agents of tuberculosis (TB), is one of the most successful human pathogens, infecting nearly one-third of the people all around the world, causing over 9 million new cases and 1.7 million deaths each year [1-2]. Identification of the relationships between different clinical strains of M. tuberculosis has great significance to the public health [3].
Keywords: Mycobacterium tuberculosis, Multi-locus sequence analysis, Molecular epidemiology, Tuberculosis, KatG, Rpsl -
Introduction
Tuberculosis (TB) is a chronic granulomatous disease, ranking as the second cause of death by infectious agents in 2021. Tuberculosis affects millions worldwide, with valvular TB being a rare manifestation, accounting for less than 1% of extrapulmonary TB cases. Valvular TB is often diagnosed through imaging and laboratory evaluations, and the treatment involves prolonged antibiotic therapy and might require surgical intervention for damaged cardiac valves.
Case PresentationA 60-year-old female patient with diabetes mellitus and rheumatoid arthritis was referred for a cardiac assessment prior to hand wound debridement surgery. Transthoracic echocardiography (TTE) revealed a mass on the mitral valve, and subsequent transesophageal echocardiography (TEE) confirmed a large, mobile mass with abscess-like density. A blood culture study was negative for infective endocarditis, and a biopsy of the wound revealed necrotizing granuloma positive for Mycobacterium tuberculosis. Anti-TB medication was initiated, resulting in a significant improvement in the valve mass. No cardiac complications were reported during the follow-up.
ConclusionsIn suspected cardiac TB patients with a high risk of surgery or patients reluctant to undergo an operation, quadruple chemotherapy can0 serve as a diagnostic and therapeutic tool.
Keywords: Valvular Tuberculosis, Mycobacterium tuberculosis, Extrapulmonary Tuberculosis, Transthoracic Echocardiography, Transesophageal Echocardiography -
سابقه و هدف
پیدایش مقاومت های دارویی و ظهور سویههای مایکوباکتریوم توبرکلوزیس مقاوم به درمان، کنترل این بیماری را با چالش مواجه ساخته است. بنا به آمار سازمان بهداشت جهانی (WHO)، سالانه در سراسر جهان حدود 000,500 مورد ابتلای جدید سل مقاوم به دارو گزارش میشود. با توجه به اینکه مکانیسمهای مرتبط با بروز مقاومت های دارویی به درستی شناخته نشده است و تحقیق های مختلف نشاندهنده نتایج متفاوتی است، بر آن شدیم تا به بررسی جهشهای ژن thyA در ارتباط با مقاومت به داروی پارا- آمینوسالیسیلیک اسید (PAS) بپردازیم.
روش کاردر این مطالعه توصیفی- مقطعی، در مدت سه سال تعداد 255 نمونه مثبت مایکوباکتریوم توبرکلوزیس با استفاده از روش استاندارد کشت و اسمیر جداسازی شد، سپس با انجام آزمون حساسیتسنجی دارویی 68 نمونه سل مقاوم به دارو انتخاب شد. برای بررسی جهش های ژن thyA، از روش PCR استاندارد استفاده شد و قطعه های حاصله توالییابی شدند. جهشهای منجر به تغییر کدون، با به کارگیری نرمافزارهای پیشبینی تغییرهای پروتئین آنالیز شدند. ارتباط جهشهای یافت شده با مقاومت به داروی PAS از لحاظ آماری توسط آزمون مربع کای مطالعه شد.
یافته هااز 255 نمونه مورد بررسی، 68 سویه (26/7درصد، فاصله اطمینان 21/3درصد) مقاوم به دارو تعیین شد. مجموعا 13 نمونه (19/1درصد) سویه مقاوم به PAS یافت شد که 5 سویه (38/4درصد) دارای جهش های نوکلئوتیدی مختلف در ژن thyA بودند. از لحاظ آماری ارتباط جهشهای مذکور با مقاومت آنتیبیوتیکی معنادار بود. به علاوه، نتایج آنالیز بیوانفورماتیک نشان داد که جهشهای یافتشده منجر به اختلال در عملکرد و ناپایداری در ساختار پروتئین حاصله میشوند.
نتیجه گیریطبق نتایج به دست آمده به نظر میرسد که جهش در ژن thyA با مقاومت به داروی PAS مرتبط است. همچنین یافتهها ارزش تشخیصی آنالیز قطعه های کوچک ژنومی و ابزارهای نوین بیوانفورماتیک را در شناسایی مکانیسمهای مقاومت دارویی نشان میدهد.
کلید واژگان: مایکوباکتریوم توبرکلوزیس، مقاومت دارویی، جهش ژنتیکی، آنالیز بیوانفورماتیکBackground and AimThe emergence of drug resistance and treatment- renitent Mycobacterium tuberculosis has made controlling the disease a challenge. World Health Organization (WHO) estimates that approximately 500,000 new cases of tuberculosis occur annually. Considering that mechanisms involved in drug resistance are yet to be elucidated and results of the studies are not consistent, we decided to investigate the correlation between mutations in thyA gene and resistance to para- aminosalicylic acid (PAS).
MethodsIn this descriptive cross- sectional study, a total of 255 positive MTB specimens were isolated during a three- year period using standard microscopic and culture methods from which 68 Multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis samples were selected through drug susceptibility testing. Then, to determine potential mutations in thyA gene, the fragment was amplified using conventional PCR and products were sequenced. Afterward, mutations which have been induced amino acid substitutions were evaluated with various protein prediction tools. Also, the correlation between mutations and drug resistance was statistically determined using chi-square test.
ResultsFrom 255 clinical TB samples, 68 (26.7%, CI 21.3%) MDR / or XDR-TB strains were isolated. In total, 13 (19.1%) were PAS- resistant and 5 (38.4%) of them had different nucleotide mutations in thyA gene. All of the mutations were statistically correlated with drug resistance. Moreover, the results of bioinformatics showed that identified mutations could lead to the structural and functional disruption of the protein.
ConclusionAccording to our results, mutations in thyA gene have appeared to be associated with resistance to PAS. Also, our findings have shed light on the potential of the analysis of short genomic regions and new computational tools in unraveling the molecular mechanisms of drug resistance.
Keywords: Mycobacterium tuberculosis, Drug resistance, thyA, Mutation, Bioinformatics -
Objective (s)
Tuberculosis (TB), a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), remains a health problem worldwide and this infection has the highest mortality rate among bacterial infections. Current studies suggest that intranasal administration of new TB vaccines could enhance the immunogenicity of M. tuberculosis antigens. Hence, we aim to evaluate the protective efficacy and immunogenicity of HspX/EsxS fusion protein of M. tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA through intranasal administration in a mice model.
Materials and MethodsIn the present study, the recombinant fusion protein was expressed in Escherichia coli and purified and used to prepare different nanoparticle formulations in combination with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA. Mice were intranasally vaccinated with each formulation three times at an interval of 2 weeks. Three weeks after the final vaccination, IFN-γ, IL-4. IL-17, and TGF-β concentrations in the supernatant of cultured splenocytes of vaccinated mice as well as serum titers of IgG1 and IgG2a and sIgA titers in nasal lavage were determined.
ResultsAccording to obtained results, intranasally vaccinated mice with formulations containing ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA could effectively induce IFN-γ and sIgA responses. Moreover, both HspX/EsxS/ISCOMATRIX/MPLA and HspX/EsxS/PLUSCOM/MPLA and their BCG booster formulation could strongly stimulate the immune system and enhance the immunogenicity of M. tuberculosis antigens.
ConclusionThe results demonstrate the potential of HspX/EsxS-fused protein in combination with ISCOMATRIX, PLUSCOM, and MPLA after nasal administration in enhancing the immune response against M. tuberculosis antigens. Both nanoparticles were good adjuvants in order to promote the immunogenicity of TB-fused antigens. So, nasal immunization with these formulations, could induce immune responses and be considered a new TB vaccine or a BCG booster.
Keywords: HspX, EsxS, ISCOMATRIX, MPLA, Mycobacterium tuberculosis, Nasal administration, PLUSCOM -
Journal of Medical Microbiology and Infectious Diseases, Volume:11 Issue: 4, Autumn 2023, PP 174 -178Introduction
Tuberculosis, caused by Mycobacterium tuberculosis, is one of the most common infectious diseases worldwide. Epidemiological studies of M. tuberculosis drug resistance are critical for improving patient treatment approaches and controlling the spread of tuberculosis. The present study aimed to determine antibiotic resistance among M. tuberculosis clinical isolates using the Microplate Alamar Blue Assay (MABA).
MethodsIn this descriptive cross-sectional study, 25 M. tuberculosis isolates from clinical samples were identified and confirmed using standard microbiological and biochemical tests. Then, the MIC for the antibiotics Bedaquiline, isoniazid, rifampin, ethambutol, ofloxacin, moxifloxacin, capreomycin, and streptomycin was determined using the MABA method. The results were analyzed using SPSS version 16 software.
ResultsAmong the 25 investigated isolates, the frequencies for MDR, Pre-XDR, and XDR isolates were 20%, 8%, and 32%, respectively. The highest rate of drug resistance was to isoniazid (80%), rifampicin, and ethambutol (76%), and the highest rate of sensitivity was to moxifloxacin (68%). The frequency of isoniazid mono-resistance and rifampicin mono-resistance was 5 cases (50%) and 4 cases (40%), respectively.
ConclusionOur study revealed an alarming rate of MDR and XDR M. tuberculosis strains, indicating that current first-line treatments may be ineffective for a significant number of patients. The bedaquiline resistance among the isolates with no history of previous exposure to this drug suggests unexplored resistance mechanisms. Molecular techniques to accurately identify these mechanisms may contribute to developing more effective treatment strategies to combat drug-resistant tuberculosis.
Keywords: Mycobacterium tuberculosis, Bedaquiline, Microplate Alamar Blue Assay, Multi-drug resistance, Extensive drug-resistant tuberculosis -
Investigating the Mutations in atpE and Rv0678 Genes in Mycobacterium Tuberculosis Clinical IsolatesJournal of Medical Microbiology and Infectious Diseases, Volume:11 Issue: 4, Autumn 2023, PP 179 -184Introduction
Tuberculosis (TB) caused by the bacterium Mycobacterium tuberculosis remains a critical global public health concern due to the high morbidity and mortality rates. Mutation in atpE and Rv0678 genes contributes to drug resistance in M. tuberculosis. This study investigates the antibiotic resistance patterns and mutations in atpE and Rv0678 genes in 22 M. tuberculosis clinical isolates.
MethodsDrug susceptibility testing (DST) for rifampin, isoniazid, streptomycin, capreomycin, ofloxacin, kanamycin, and ethambutol was conducted using the proportional method. This was followed by determining the minimum inhibitory concentration (MIC) for bedaquiline (BDQ) via the microplate Alamar blue assay (MABA). Genomic regions encompassing atpE and Rv0678 genes were amplified and sequenced for mutation analysis. Data analysis was performed using SPSS software to interpret mutation patterns concerning drug susceptibility profiles.
ResultsOf 22 isolates, 5 (27.8%) were extensively drug-resistant tuberculosis (XDR-TB), and 13 (72.2%) were multi-drug resistant tuberculosis (MDR-TB). Resistance rates to kanamycin, ofloxacin, capreomycin, and streptomycin were 40.6%, 46.3%, 85%, and 74.6%, respectively. Additionally, phenotypic resistance to bedaquiline was observed in 12 (54.5%) isolates. Sequencing revealed no resistance-conferring mutations in the atpE or Rv0678 genes among the isolates.
ConclusionOur findings showed substantial resistance to first- and second-line drugs in M. tuberculosis clinical isolates. This highlights the necessity for ongoing, comprehensive studies to elucidate the evolving drug resistance patterns and understand the underlying mechanisms in clinical isolates.
Keywords: Mycobacterium tuberculosis, DST, atpE, Rv0678, Bedaquiline, Extensively drug-resistant tuberculosis (XDR-TB), Multi-drug resistant tuberculosis (MDR-TB) -
Background and Objectives
The role of microRNAs (miRNAs) in tuberculosis infection is well established. As microR- NAs are able to change expression profiles according to different conditions, they can be useful biomarkers. Iranians and Afghans with tuberculosis were studied for three immune-related miRNAs (miR-let-7f, miR-125a, and miR-125b).
Materials and MethodsA total of 60 Iranian and Afghan patients with active pulmonary TB were enrolled in the Pulmo- nary Department of the Pasteur Institute of Iran. Serum and sputum samples were collected simultaneously from all partici- pants. A Real-time PCR was conducted to detect differentially expressed miRNAs.
ResultsIranian (P<0.0001) and Afghan (P<0.0001) serum samples and Afghan (P<0.0001) sputum samples overexpressed miR-125a, whereas Iranian sputum samples showed downregulation (P=0.0039). In both Iranian (P<0.0001; P=0.0007) and Afghan (P<0.0001; P<0.0001) serum and sputum samples, miR-125b was overexpressed. Furthermore, miR-let-7f down- regulation was observed in serum and sputum samples (P<0.0001), whereas Iranian sputum samples had no statistically significant differences (P=0.348).
ConclusionOverexpression of miR-125a and miR-125b has been detected in Iranian and Afghan samples. In both races, miR-let-7f downregulation has been confirmed. Identification of miRNA profiles under different conditions opens the door to evaluating potential new biomarkers for diagnosis, disease monitoring, and therapeutic markers in TB infection.
Keywords: Mycobacterium tuberculosis, MicroRNA, Sputum, Serum -
شیوع عفونت سل نهفته بر حسب منطقه به طور چشمگیری متفاوت است. در حال حاضر یک چهارم جمعیت جهان به سل نهفته مبتلا هستند. جهت رسیدن به اهداف سازمان بهداشت جهانی جهت پایان سل در سراسر جهان تا سال 2030 تعداد افراد مبتلا به سل نهفته که به سمت سل فعال پیشرفت می کنند باید کاهش یابد. تست های رایج که جهت تشخیص سل نهفته کاربرد دارد بر اساس پاسخ ایمنی به آنتی ژن های اختصاصی مایکوباکتریوم توبرکلوزیس به دو نوع تست های پوستی و تست های مبتنی بر اندازه گیری اینترفرون گاما تقسیم بندی می شوند. با این وجود هر دو تست دارای حساسیت پایینی هستند و نمی توانند بین سل نهفته و سل فعال تمایز قائل شوند. بنابراین، تکنیک های مختلفی مانند تشخیص سیتوکین های جایگزین و استفاده از آنتی ژن های جدید برای افزایش دقت این آزمایش ها در حال مطالعه هستند. علاوه بر این، آنتی ژن های جدید را می توان برای نظارت بر پیشرفت سل فعال و پاسخ به درمان استفاده کرد. هدف از این مطالعه بررسی ابزارهای تشخیصی و شواهد موجود در مورد آنتی ژن های جدید مایکوباکتریوم توبرکلوزیس برای تشخیص سل نهفته و انتخاب آنتی ژن های امیدوارکننده برای تحقیقات آینده است.
کلید واژگان: مایکوباکتریوم توبرکلوزیس، سل نهفته، تست های مبتنی بر رهاسازی اینترفرون گاما، مطالعه بالینی، تست های سرولوژیکLatent tuberculosis infection (LTBI) prevalence varies dramatically by region, with one-fourth of the world's population infected. The number of people with LTBI progressing to active tuberculosis illness (aTB) should be decreased to meet the WHO End TB Strategy objective of decreasing worldwide tuberculosis incidence by 2030. Current tuberculosis (TB) diagnostic methods are based on detecting an immune response to mycobacterial antigens injected into the skin or in vitro simulations in interferon-gamma release assays. Both tests have low sensitivity, which cannot distinguish between LTBI and aTB. Therefore, various techniques, such as alternate cytokine detection and employing novel antigens, are being studied to increase the accuracy of these tests. In addition, novel antigens can be used to monitor aTB progression and response to treatment. This review aims to assess current available diagnostic tools and evidence on novel Mycobacterium tuberculosis (Mtb) antigens for LTBI diagnosis and select the most promising antigens for future research.
Keywords: Mycobacterium tuberculosis, Latent Tuberculosis, Interferon-gamma Release Tests, Clinical Study, Serologic Tests -
سابقه و هدف
با توجه به اهمیت نگرانی از میزان مقاوم بودن RIF و با توجه به آمار سازمان جهانی بهداشت 399000-501000 گزارش کردند و با اطلاع نداشتن از این وضعیت در تهران این مورد گزارش شد. هدف از این مطالعه استفاده از روش GeneXpert MTB / RIF برای ارزیابی الگوهای مقاومت RIF در موارد سل ریوی خلط مثبت و تست مقاومت RIF در سویه های MTB موارد مشکوک بالینی MDR- TB در تهران بود.
روش کارتحقیق روش توصیفی انجام شده از اول فروردین 1400 تا 30 اسفند 1400 انجام شد. روش و تحقیق توصیفی روی 1000 نمونه بالینی افراد مشکوک به سل انجام شد. همه نمونه ها در مرکز سل استان مورد مطالعه برای آزمایش میکروسکوپی و کشت قرار گرفتند. آزمایش حساسیت دارویی به داروی خط اول ضد سل برای کشت MTB مثبت روی محیط کشت Löwenstein- Jensen (LJ) به روش نسبت انجام شد. تمام ایزوله های مقاوم و حساس به RIF توسط GeneXpert شناسایی شدند و شیوع میزان مقاومت در نمونه ها تعیین و میزان واقعی آن در جامعه برآورد شده است. سپس با استفاده از نرم افزار SPSS میزان مقاومت و عوامل موثر بر آن بررسی شدند.
یافته هابا توجه به این شیوع در این نمونه ها در این تحقیق از 440 نمونه مثبت تعداد سه نمونه مثبت یا 0/07 درصد مقاوم بوده است.
نتیجه گیریبه نظر می رسد مقاومت به ریفامپین مسیله خیلی بزرگی نیست و جای نگرانی نیست. در نتیجه، شیوع مقاومت دارویی در این منطقه مطالعه شده نسبتا پایین بود. پیشنهاد ما این است که مطالعه های بیشتری در مناطق مختلف این کشور انجام شود تا کارایی GeneXpert و اینکه آیا می تواند در ایران مفید و موثر باشد، ارزیابی شود.
کلید واژگان: مقاوم به ریفامپیسین، مایکوباکتریوم توبرکلوزیس، مقاوم به چند دارو، سنجش مایکو باکتریوم توبرکلوزیس، ریفامپیسین ژن اکسپرتBackground and AimMultidrug- resistant (MDR) tuberculosis (TB) is caused by a strain of Mycobacterium tuberculosis (MTB) that was at least resistant to isoniazid (INH) and rifampicin (RIF). World Health Organization reported 399,000-501,000 cases of RIF resistance and they reported this case without knowing about this situation in Tehran. So, it is an important concern.
MethodsDescriptive method and research was done on 1000 clinical samples of people suspected of tuberculosis. All the samples were studied in the TB center of the province for microscopic examination and culture. Using the ratio method, the drug sensitivity test to the first- line anti- tuberculosis drug was performed for positive MTB cultures on Löwenstein- Jensen (LJ) culture medium. All isolates resistant and sensitive to RIF were identified by GeneXpert and the prevalence of resistance in the samples was determined and its actual level in the community was estimated. Then, using SPSS software, the level of resistance and factors affecting it were checked.
ResultsAccording to theprevalence in these samples in this research, out of 440 positive samples, 3 positive samples, or 0.07% were resistant.
ConclusionIt seems that resistance to rifampin is not a big problem and is not a cause for concern. As a result, the prevalence of drug resistance in this study area was relatively low. Our suggestion is to conduct more studies in different regions of this country to evaluate the efficiency of GeneXpert and whether it can be useful and effective in Iran.
Keywords: Rifampicin Resistance, Mycobacterium Tuberculosis, Multi- Drug Resistance, GeneXpert MTB, RIF assay
- نتایج بر اساس تاریخ انتشار مرتب شدهاند.
- کلیدواژه مورد نظر شما تنها در فیلد کلیدواژگان مقالات جستجو شدهاست. به منظور حذف نتایج غیر مرتبط، جستجو تنها در مقالات مجلاتی انجام شده که با مجله ماخذ هم موضوع هستند.
- در صورتی که میخواهید جستجو را در همه موضوعات و با شرایط دیگر تکرار کنید به صفحه جستجوی پیشرفته مجلات مراجعه کنید.